公开(公告)号：US07850965B2

公开(公告)日：2010-12-14

申请号：US11633070

申请日：2006-12-04

申请人： Allan Jensen ,  Johan Lantto ,  Margit Haahr Hansen ,  Lone Kjær Rasmussen ,  Søren Kofoed Rasmussen ,  Lucilla Steinaa

发明人： Allan Jensen ,  Johan Lantto ,  Margit Haahr Hansen ,  Lone Kjær Rasmussen ,  Søren Kofoed Rasmussen ,  Lucilla Steinaa

IPC分类号： A61K39/00 ,  A61K39/42 ,  C07K16/08

CPC分类号： C07K16/081 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92

摘要： Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as therapeutic methods utilizing the polyclonal antibody. Finally, the invention also pertains to a method for screening for useful VH and VL pairs useful when preparing the polyclonal antibody.

摘要翻译： 公开了一种抗正痘病毒重组多克隆抗体，其包含能够结合至少三种正痘病毒相关抗原的不同成员，包含该抗体的药物组合物及其制备方法。 还公开了能够产生重组多克隆抗体作为利用多克隆抗体的治疗方法的多克隆细胞系。 最后，本发明还涉及筛选在制备多克隆抗体时有用的有用的VH和VL对的方法。

公开(公告)号：US07887805B2

公开(公告)日：2011-02-15

申请号：US12074056

申请日：2008-02-29

申请人： Mikkel Wandahl Pedersen ,  Lucilla Steinaa ,  Allan Jensen ,  Klaus Koefoed ,  Per-Johan Meijer ,  Robert Carlsson ,  Charles Pyke ,  Lars S. Nielsen

发明人： Mikkel Wandahl Pedersen ,  Lucilla Steinaa ,  Allan Jensen ,  Klaus Koefoed ,  Per-Johan Meijer ,  Robert Carlsson ,  Charles Pyke ,  Lars S. Nielsen

IPC分类号： A61K39/395 ,  C07K14/71 ,  C12N15/13

CPC分类号： C07K16/2863 ,  A61K39/39558 ,  A61K2039/507 ,  C07K14/71 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/92 ,  A61K2300/00

摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.

摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供能够结合人EGFR的抗体的组合物或混合物。 具有3种或更多种抗体的抗体组合物在代表性癌细胞系的增殖减少方面表现出协同作用。 使用包含两种不同的嵌合抗hEGFR抗体的组合物也获得了有利的结果，其显示出基于动物模型中快速且有效的受体内化，诱导终末分化和随后的肿瘤根除的新作用机制。 本发明的抗体可以作为多克隆抗体在一个生物反应器中制造。

公开(公告)号：US20100040606A1

公开(公告)日：2010-02-18

申请号：US11792927

申请日：2007-03-06

申请人： Johan Lantto ,  Lucilla Steinaa ,  Klaus Koefoed

发明人： Johan Lantto ,  Lucilla Steinaa ,  Klaus Koefoed

IPC分类号： A61K39/395 ,  C07K16/08 ,  C12P19/34 ,  C12N5/00 ,  A61P31/12 ,  A61K39/42 ,  C07H21/00 ,  C12N15/63

CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C12N2760/18511

摘要： Disclosed are novel polyclonal antibodies, which target respiratory syncyticilal virus (RSV), and novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of epitopes on these proteins. The single antibody molecules of the invention are shown to exhibit affinities which provide for dissociation constants as low as in the picomolar range. Also disclosed are methods of producing the antibodies of the invention as well as methods of their use in treatment for RSV infection.

摘要翻译： 公开了靶向呼吸道合胞体病毒（RSV）的新型多克隆抗体，以及与RSV反应的新型高亲和力抗体分子。 多克隆抗体可以包含与RSV蛋白F和RSV蛋白G两者都具有反应性的抗体分子，优选多克隆抗体靶向这些蛋白质上的多种表位。 本发明的单抗体分子显示出亲和力，其提供的解离常数低于皮摩尔范围。 还公开了制备本发明的抗体的方法以及它们用于治疗RSV感染的方法。

公开(公告)号：US07820633B2

公开(公告)日：2010-10-26

申请号：US10441779

申请日：2003-05-19

申请人： Lucilla Steinaa ,  Jesper Haaning ,  Iben Dalum ,  Peter Birk ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Anand Gautam ,  Søren Mouritsen

发明人： Lucilla Steinaa ,  Jesper Haaning ,  Iben Dalum ,  Peter Birk ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Anand Gautam ,  Søren Mouritsen

IPC分类号： A61K31/70 ,  A61K31/711 ,  C12N15/00 ,  C07H21/04

CPC分类号： C07K16/3069 ,  A61K39/0011 ,  C07K14/50 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/71 ,  C07K2317/34 ,  C12N2799/021 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

公开(公告)号：US07807441B2

公开(公告)日：2010-10-05

申请号：US11202516

申请日：2005-08-11

申请人： Lucilla Steinaa ,  Søren Mouritsen ,  Anand Gautam ,  Iben Dalum ,  Jesper Haaning ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Peter Birk Rasmussen

发明人： Lucilla Steinaa ,  Søren Mouritsen ,  Anand Gautam ,  Iben Dalum ,  Jesper Haaning ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Peter Birk Rasmussen

IPC分类号： C12N1/00 ,  C12N1/10 ,  C12N1/14 ,  C12N1/16 ,  C12N1/20 ,  C12N5/10 ,  C12N5/14 ,  C12N5/16 ,  C12N15/00 ,  A61K38/00 ,  C07K14/00

CPC分类号： C07K16/3069 ,  A61K39/0011 ,  C07K14/50 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/71 ,  C07K2317/34 ,  C12N2799/021 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

摘要翻译： 公开了一种用于诱导针对细胞抗原的细胞介导的免疫的方法。 更具体地，本发明提供了一种诱导针对弱抗原，特别是自身蛋白的细胞毒性T淋巴细胞免疫的方法。 该方法需要抗原呈递细胞被诱导以呈现弱抗原的至少一个CTL表位，并且同时呈现至少一种外来T辅助淋巴细胞表位。 在优选的实施方案中，抗原是癌特异性抗原，例如 PSM，Her2或FGF8b。 该方法可以通过使用传统的多肽疫苗接种，也可以通过使用活减毒疫苗或核酸接种来进行。 本发明还提供了PSM，Her2和FGF8b的免疫原性类似物以及编码这些类似物的核酸分子。 还公开了载体和转化的细胞。 本发明还提供了用于鉴定弱或非免疫原性抗原的免疫原性类似物的方法。

公开(公告)号：US20080253993A1

公开(公告)日：2008-10-16

申请号：US11909983

申请日：2006-03-30

申请人： Lucilla Steinaa ,  Valery Renard

发明人： Lucilla Steinaa ,  Valery Renard

IPC分类号： A61K45/00 ,  A61K39/00 ,  A61K38/21 ,  A61K9/127 ,  C07K14/00 ,  C12N15/11 ,  C12N15/00 ,  C12N1/20 ,  C12N15/74 ,  A61P37/00

CPC分类号： C07K14/71 ,  A61K9/0019 ,  A61K38/00 ,  A61K39/0011 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/6037 ,  A61K2039/6043 ,  A61K2039/6075 ,  Y02A50/412

摘要： Disclosed is a method for inducing an immune response against autologous Epidermal Growth Factor Receptor (EGFR) in humans. The method comprises effecting uptake by antigen presenting cells of epitopes (preferably all) from the extracellular portion of human EGFR and of at least one non-human T helper epitope (TH epitope) so as to induce antibodies against EGFR. Immunization may be accomplished by protein vaccination, nucleic acid vaccination and live or viral vaccination. The immune response is useful in treatment of malignancies. Also disclosed are modified EGFR proteins and expression plasmids useful for the immunization method as well as recombinant gene technology tools such as nucleic acids, vectors and host cells.

摘要翻译： 公开了一种在人体中诱导针对自体表皮生长因子受体（EGFR）的免疫应答的方法。 该方法包括通过来自人EGFR细胞外部分和至少一个非人T辅助表位（T H H H表位）的表位（优选全部）的抗原呈递细胞进行摄取，以诱导抗体 针对EGFR。 免疫可以通过蛋白质接种，核酸接种和活的或病毒接种来完成。 免疫反应可用于治疗恶性肿瘤。 还公开了可用于免疫方法的修饰的EGFR蛋白和表达质粒以及重组基因技术工具，例如核酸，载体和宿主细胞。

公开(公告)号：US20110158984A1

公开(公告)日：2011-06-30

申请号：US12965437

申请日：2010-12-10

申请人： Allan Jensen ,  Johan Lantto ,  Margit Haahr Hansen ,  Lone Kjær Rasmussen ,  Søren Kofoed Rasmussen ,  Lucilla Steinaa

发明人： Allan Jensen ,  Johan Lantto ,  Margit Haahr Hansen ,  Lone Kjær Rasmussen ,  Søren Kofoed Rasmussen ,  Lucilla Steinaa

IPC分类号： A61K39/42 ,  C07K16/08 ,  C12Q1/70 ,  C12P19/34 ,  C12N5/16 ,  A61P31/12

CPC分类号： C07K16/081 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92

摘要： Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as therapeutic methods utilizing the polyclonal antibody. Finally, the invention also pertains to a method for screening for useful VH and VL pairs useful when preparing the polyclonal antibody.

摘要翻译： 公开了一种抗正痘病毒重组多克隆抗体，其包含能够结合至少三种正痘病毒相关抗原的不同成员，包含该抗体的药物组合物及其制备方法。 还公开了能够产生重组多克隆抗体作为利用多克隆抗体的治疗方法的多克隆细胞系。 最后，本发明还涉及筛选在制备多克隆抗体时有用的有用的VH和VL对的方法。

公开(公告)号：US20110129855A1

公开(公告)日：2011-06-02

申请号：US12945495

申请日：2010-11-12

申请人： MIKKEL WANDAHL PEDERSEN ,  LUCILLA STEINAA ,  ALLAN JENSEN ,  KLAUS KOEFOED ,  PER-JOHAN MEIJER ,  ROBERT CARLSSON ,  CHARLES PYKE ,  LARS SOGAARD NIELSEN

发明人： MIKKEL WANDAHL PEDERSEN ,  LUCILLA STEINAA ,  ALLAN JENSEN ,  KLAUS KOEFOED ,  PER-JOHAN MEIJER ,  ROBERT CARLSSON ,  CHARLES PYKE ,  LARS SOGAARD NIELSEN

IPC分类号： C07K16/00 ,  C12P21/02 ,  C12N5/10 ,  C07H21/04 ,  C12N15/63 ,  G01N33/68

CPC分类号： C07K16/2863 ,  A61K39/39558 ,  A61K2039/507 ,  C07K14/71 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/92 ,  A61K2300/00

摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.

公开(公告)号：US20090004192A1

公开(公告)日：2009-01-01

申请号：US12074056

申请日：2008-02-29

申请人： Mikkel Wandahl Pedersen ,  Lucilla Steinaa ,  Allan Jensen ,  Klaus Koefoed ,  Per-Johan Meuer ,  Robert Carlsson ,  Charles Pyke ,  Lars Sogaard Nielsen

发明人： Mikkel Wandahl Pedersen ,  Lucilla Steinaa ,  Allan Jensen ,  Klaus Koefoed ,  Per-Johan Meuer ,  Robert Carlsson ,  Charles Pyke ,  Lars Sogaard Nielsen

IPC分类号： A61K39/395 ,  G01N33/566 ,  C12N15/12 ,  C07K14/47 ,  C07K16/22 ,  C12N15/85 ,  A61P35/00 ,  C12P21/02 ,  C12N5/16 ,  C12N5/10

CPC分类号： C07K16/2863 ,  A61K39/39558 ,  A61K2039/507 ,  C07K14/71 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/92 ,  A61K2300/00

摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.

摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供能够结合人EGFR的抗体的组合物或混合物。 具有3种或更多种抗体的抗体组合物在代表性癌细胞系的增殖减少方面表现出协同作用。 使用包含两种不同的嵌合抗hEGFR抗体的组合物也获得了有利的结果，其显示基于动物模型中快速且有效的受体内化，诱导终末分化和随后的肿瘤根除的新作用机制。 本发明的抗体可以作为多克隆抗体在一个生物反应器中制造。

公开(公告)号：US20080069822A1

公开(公告)日：2008-03-20

申请号：US11633070

申请日：2006-12-04

申请人： Allan Jensen ,  Johan Lantto ,  Margit Hansen ,  Lone Rasmussen ,  Soren Rasmussen ,  Lucilla Steinaa

发明人： Allan Jensen ,  Johan Lantto ,  Margit Hansen ,  Lone Rasmussen ,  Soren Rasmussen ,  Lucilla Steinaa

IPC分类号： A61K39/395 ,  A61P43/00 ,  C07K16/18 ,  C12N5/06 ,  C12P19/34 ,  C12Q1/70

CPC分类号： C07K16/081 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92

摘要： Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as therapeutic methods utilizing the polyclonal antibody. Finally, the invention also pertains to a method for screening for useful VH and VL pairs useful when preparing the polyclonal antibody.

摘要翻译： 公开了一种抗正痘病毒重组多克隆抗体，其包含能够结合至少三种正痘病毒相关抗原的不同成员，包含该抗体的药物组合物及其制备方法。 还公开了能够产生重组多克隆抗体作为利用多克隆抗体的治疗方法的多克隆细胞系。 最后，本发明还涉及用于筛选在制备多克隆抗体时有用的有用的V H和V L配对的方法。